Angiotensin converting enzyme inhibitors do not increase the risk of poor outcomes in COVID-19 disease. A multi-centre observational study

BACKGROUND AND AIMS: Hypertension is associated with an increased risk of severe outcomes with COVID-19 disease. Angiotensin Converting Enzyme (ACE) inhibitors are widely used as a first line medication for the treatment of hypertension in the UK, although their use was suggested in early reports to...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Khurram Shahzad, Reed-Embleton, Hamish, Lewis, Jen, Bain, Pamela, Mahmud, Sajid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468667/
https://www.ncbi.nlm.nih.gov/pubmed/32873147
http://dx.doi.org/10.1177/0036933020951926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7468667/
https://www.ncbi.nlm.nih.gov/pubmed/32873147
http://dx.doi.org/10.1177/0036933020951926

Ejemplares similares